๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060

โœ Scribed by Elizabeth A. Poplin; Joth Jacobson; Arnold Herskovic; Timothy J. Panella; Manuel Valdivieso; Laura F. Hutchins; John S. Macdonald

Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
598 KB
Volume
78
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis

BACKGROUND.

Continuous infusion 5-fluorouracil (CI5-FU) has been utilized concurrently with radiotherapy to improve tumor control. In this pilot trial, cisplatin, C15FU, and radiotherapy were utilized for the treatment of locoregional esophageal carcinoma. It was postulated that the combination would be well tolerated and associated with high response rate and survival duration. METHODS. Thirty-two eligible patients with locoregional squamous cell carcinoma and adenocarcinoma of the esophagus received a regimen consisting of the following: radiotherapy, SO Gray (Cy) (30 Gy anteroposteriorlposteroanterior regional with 20 Gy APILPOIRPO boost) over S weeks, with CI5-FU 250 mglm2/d for the duration of radiotherapy and cisplatin 25 mg/m2/day on Days 1-3 during Weeks 1 and 4 of the radiotherapy cycle. Upon completion of radiotherapy, two additional courses of cisplatin 75 mg/m2 on Days 1 and 29 and CIS-FU 300 mglm'lday on Days 1-21 and 29-50 were delivered. Following imaging and endoscopic reassessment, patients with no evidence of disease received more chemotherapy. Surgery was suggested only for patients with residual local disease.

RESULTS.

Complete response was demonstrated in 44% of patients, clinically in 12 patients, and during surgery in 2 others. The median survival was 20 months, and the 1-year survival rate was 59%. Toxicity was severe, comprised of esophagitis, infection, and gastrointestinal complications. Dose delays and reductions occurred in the majority of patients. Four early deaths were noted. CONCLUSIONS. The regimen that was the focus of this trial has been active in the treatment of esophageal carcinoma. However, compared with existing regimens, its complexity and toxicity preclude its future use without modifications. Cancer

๐Ÿ“œ SIMILAR VOLUMES

Evaluation of cisplatin, carboplatin, an
Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma: A phase II study of the Southwest Oncology Group
โœ Robert A. Figlin; John J. Crowley; Edwin L. Jacobs; Michael Muirhead; John Wenda ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 587 KB

## BACKGROUND. The combined use of cisplatin and carboplatin chemotherapy offers a unique means of platinum dose intensification. Response rates using either of these agents in combination with etoposide are comparable. In a Phase II trial, the authors investigated the combination of cisplatin and

Evaluation of low dose continuous infusi
Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study
โœ Julie A. Kish; Michael Wolf; E. David Crawford; Joseph T. Leimert; Anton Buesche ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 289 KB ๐Ÿ‘ 2 views

Background. The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5-fluorouracil(5-FU) has demonstrated efficacy in other cytotoxic refractory tumors, such as pancreas, colorectal, and recurrent breast. The Southwest Oncology

Phase II evaluation of cisplatin and eto
Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma : A Southwest Oncology Group study
โœ Stephen K. Williamson; Danika Lew; Gary J. Miller; Stanley P. Balcerzak; Laurenc ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 77 KB ๐Ÿ‘ 2 views

## Background: A previous southwest oncology group study demonstrated a 30% response rate with the combination of cisplatin and mitotane in the treatment of patients with metastatic adrenocortical carcinoma. several case reports suggested that the combination of etoposide and cisplatin may be an ac

Teniposide (VM-26) as a single drug trea
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma : A Phase II study of the Southwest Oncology Group
โœ Petre N. Grozea; John J. Crowley; Vikki A. Canfield; Laura Kingsbury; S. William ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 74 KB ๐Ÿ‘ 3 views

## Background: Teniposide (vm-26) was reported to have activity in small cell lung carcinoma (sclc). the authors performed a phase ii study of teniposide as a treatment for patients with previously untreated extensive sclc. ## Methods: The study was open to patients with a histologic or cytologic